You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

multi-kinase inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

Not yet recruiting
  • Liver Transplant; Complications
  • +3 more
  • multi-kinase inhibitors in combination with bevacizumab
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma Trial in Rochester

Completed
Has Results
  • Malignant Adrenal Gland Pheochromocytoma
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
Sep 28, 2022

Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy Trial in Philadelphia (Netarsudil 0.02% Ophthalmic Solution

Not yet recruiting
  • Rhegmatogenous Retinal Detachment
  • Proliferative Vitreoretinopathy
  • Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
  • Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
  • Philadelphia, Pennsylvania
    Wills Eye Physicians - Mid Atlantic Retina
Dec 13, 2022

GastroEsophageal Cancer, Gastric Cancer Trial in New York (Lenvatinib, Pembrolizumab)

Recruiting
  • GastroEsophageal Cancer
  • Gastric Cancer
  • New York, New York
  • +1 more
Aug 12, 2022

Advanced Carcinoid Tumor, Digestive System Neuroendocrine Tumor, Multiple Endocrine Neoplasia Type 1 Trial in Houston

Recruiting
  • Advanced Carcinoid Tumor
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous

Recruiting
  • High Grade Fallopian Tube Serous Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer Trial (ART0380)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • (no location specified)
Apr 5, 2023

Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

Active, not recruiting
  • Liposarcoma
  • Metastatic Liposarcoma
  • Boston, Massachusetts
  • +2 more
Nov 23, 2022

Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Trial in Columbus (Lenvatinib Mesylate,

Completed
  • Fallopian Tube Carcinoma
  • +3 more
  • Lenvatinib Mesylate
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 5, 2022

Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8

Recruiting
  • Recurrent Hepatocellular Carcinoma
  • +7 more
  • Scottsdale, Arizona
  • +1 more
Jun 16, 2022

Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 17, 2022

Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic

Active, not recruiting
  • Columnar Cell Variant Thyroid Gland Papillary Carcinoma
  • +25 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Torrance, California
  • +6 more
Jan 12, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma Trial in Atlanta

Terminated
  • Differentiated Thyroid Gland Carcinoma
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jun 25, 2021

Advanced / Metastatic Solid Tumors Trial (MAX-40279-01: 50mg/70mg)

Not yet recruiting
  • Advanced / Metastatic Solid Tumors
  • MAX-40279-01: 50mg/70mg
  • (no location specified)
Jun 16, 2022

Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Trial in United States

Recruiting
  • Metastatic Renal Cell Carcinoma
  • +3 more
  • Avelumab
  • +7 more
  • Danville, Illinois
  • +4 more
Jul 29, 2022

Uveal Melanoma Trial in Worldwide (LXS196, LXS196 and HDM201)

Terminated
  • Uveal Melanoma
  • New York, New York
  • +5 more
Sep 27, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Cushing Disease Trial (Fimepinostat)

Not yet recruiting
  • Cushing Disease
  • (no location specified)
Jul 31, 2023